Reevaluating First-line Therapies in Youth-Onset Type 2 Diabetes

被引：2

作者：

Chung, Stephanie T. ^{[1
,2
,3
]}

Davis, Faith ^{[1
]}

Patel, Tejal ^{[2
]}

Mabundo, Lilian ^{[1
]}

Estrada, Doris E. ^{[2
]}

机构：

[1] Natl Inst Diabet & Digest & Kidney Dis, Sect Pediat Diabet Obes & Metab, NIH, Bethesda, MD 20892 USA

[2] Childrens Natl Hosp, Div Endocrinol & Diabet, Washington, DC 20010 USA

[3] Natl Inst Diabet & Digest & Kidney Dis, NIH, 10 Ctr Dr, Bld 10-CRC,RM 5-5942, Bethesda, MD 20892 USA

来源：

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2024年 / 109卷 / 02期

基金：

美国国家卫生研究院;

关键词：

pediatric; type; 2; diabetes; medication; metformin; treatment;

D O I：

10.1210/clinem/dgad508

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The prevalence of youth-onset type 2 diabetes is growing worldwide and current first-line treatment with metformin and intensive behavior and lifestyle changes are suboptimal in over 50% of youth within 2 years of diagnosis. This perspective article is a call to action for reevaluation of existing strategies and critical appraisal of metformin as first-line therapy in youth-onset type 2 diabetes. Increased attention should be given to novel therapeutics approved in youth, including glucagon-like 1 receptor agonists, sodium glucose cotransporter-2, and sociocultural interventions that will promote diabetes self-management.

引用

页码：e870 / e872

页数：3